FDA approves Enbrel to treat psoriasis
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., April 30, 2004 Amgen (N), today announced that Enbrel® (etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYEministration (FDA) for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy...Enbrel shown safe, effective in children and teenagers with juvenile rheumatoid arthritis
. Enbrel® (etanercept) has been shown to be a safe and effective drug in the treatment of children and. teenagers with polyarticular juvenile rheumatoid arthritis (JRA), according to clinical trial results. reported in the New England Journal of Medicine. . . In this clinical trial, 69 children, ages 4 to 17, were injected with Enbrel® twice a week; 74. percent responded with mea...ENBREL (etanercept) long-term clinical trial data
BOSTON - Data from patients receiving ENBREL® (etanercept) for as long as 41 months were presented at the 63rd National Scientific Meeting of the American College of Rheumatology (ACR) today. ... ...The FDA approved ENBREL on November 2, 1998 to treat moderately to severely active rheumatoid arthritis in patients who have an inadequate response to one or more disease-modifying anti-rheumatic.... New Approval Sought for ENBREL to Slow Joint Damage and Improve the Signs and.Symptoms of Early, Active Rheumatoid Arthritis . .SEATTLE - Immunex Corporation (NASDAQ: IMNX) announced today that the company.has filed a supplemental biologics license application (sBLA) with the U.S. Food.and Drug Administration (FDA) for ENBRELR (etanercept), seeking a new label for.the drug to slow structural d...Circulation publishes phase I study of ENBREL in patients with chronic heart failure
.SEATTLE - A Phase I study published today in CIRCULATION: Journal of the.American Heart Association, demonstrates ENBREL® (etanercept, a soluble TNF p75.receptor) was well tolerated in patients with advanced heart failure. The study.also suggests that ENBREL may lead to improvement in the functional status of.patients with chronic heart failure. This is the first published paper of an.ENBR...ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
. Therapeutic Breakthrough For Rheumatoid Arthritis Becomes First Biologic.Response Modifier Approved To Treat Children And Teen-Agers With JRA . .SEATTLE - ENBREL® (etanercept) was approved today by the U.S. Food and Drug.Administration (FDA) for the treatment of moderately to severely active.polyarticular-course juvenile rheumatoid arthritis (JRA) in patients who have.had an inadequate res.... Immunex Plans To File With The FDA Seeking An Expanded Label For ENBREL To Slow.Structural Joint Damage In Patients And to Improve The Signs And Symptoms Of.Patients With Early, Active RA . .SEATTLE - In patients with early, active rheumatoid arthritis (RA), the primary.endpoints from a Phase III study showed that ENBREL® (etanercept) slowed the.progression of the disease and reduced the...ENBREL (Etanercept) Patient And Physician Support Web Site Launched
. Web Site Offers Important Information And Support Programs For People With.Rheumatoid Arthritis And For Their Health Care Providers . .SEATTLE, April 6, 1999 - In an effort to better educate patients and health care.providers about ENBREL (etanercept), a breakthrough treatment for rheumatoid.arthritis (RA), Immunex Corporation and Wyeth-Ayerst Pharmaceuticals have.launched the ENBREL Web Site...ENBREL Phase III Data Published In Annals Of Internal Medicine
. . . Immunex Corporation (NSQD:IMNX) and Wyeth-Ayerst Laboratories, a.division of American Home Products Corporation (NYSE:AHP), announce the.publication of Phase III data for ENBREL (etanercept) for the treatment of.rheumatoid arthritis (RA) in the Annals of Internal Medicine. . . The six month study is based on 234 patients with active rheumatoid.arthritis with inadequate response to D...